Department of Medicine, Division of Infectious Diseases, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
Department of Hospital Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
Microbiol Spectr. 2023 Feb 14;11(1):e0409222. doi: 10.1128/spectrum.04092-22. Epub 2023 Jan 23.
The test performance and potential clinical utility of the ePlex blood culture identification Gram-negative (BCID-GN) panel was evaluated relative to matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry on bacterial isolates and conventional antimicrobial susceptibility testing. The majority (106/108, 98.1%) of GN bacteria identified by MALDI were on the BCID-GN panel, and valid tests (107/108, 99.1%) yielded results on average 26.7 h earlier. For all valid tests with on-panel organisms, the positive percent agreement was 102/105 (97.2%) with 3 false negatives and the negative percent agreement was 105/105. Chart review ( = 98) showed that in conjunction with Gram stain results, negative pan-Gram-positive (GP) markers provided the opportunity to discontinue GP antibiotic coverage in 63/98 (64.3%) cases on average 26.2 h earlier. Only 8/12 (66.7%) isolates with resistance to third-generation cephalosporins harbored the CTX-M gene. In contrast, 8/8 CTX-M samples yielded a resistant isolate. Detection of 1 Stenotrophomonas maltophilia (18 h), 1 OXA23/48 Acinetobacter baumannii (52.4 h), and 3 CTX-M isolates on ineffective treatment (47.1 h) and 1 on suboptimal therapy (72.6 h) would have additionally enabled early antimicrobial optimization in 6/98 (6.1%) patients. The GenMark Dx ePlex rapid blood culture diagnostic system enables earlier time to identification of antimicrobial-resistant Gram-negative bacteria causing bloodstream infections. Its ability to rule out Gram-positive bacteria enabled early discontinuation of unnecessary antibiotics in 63/98 (64.3%) cases on average 26.2 h earlier. Detection of bacteria harboring the CTX-M gene as well as early identification of highly resistant bacteria such as Stenotrophomonas maltophilia and Acinetobacter baumannii enabled optimization of ineffective therapy in 6/98 (6.1%) patients. Its implementation in clinical microbiology laboratories optimizes therapy and improves patient care.
该 ePlex 血培养鉴定革兰氏阴性(BCID-GN)面板的检测性能和潜在临床应用价值相对于基质辅助激光解吸电离飞行时间(MALDI-TOF)质谱法对细菌分离株和常规抗菌药物敏感性测试进行了评估。通过 MALDI 鉴定的革兰氏阴性菌中,有 106/108(98.1%)在 BCID-GN 面板上,并且有效的测试(107/108,99.1%)平均提前 26.7 小时得出结果。对于所有有面板生物体的有效测试,阳性百分比一致率为 102/105(97.2%),有 3 个假阴性,阴性百分比一致率为 105/105。图表审查( = 98)显示,与革兰氏染色结果相结合,革兰氏阳性(GP)标志物的阴性 pan-GP 标志物平均为 63/98(64.3%)患者提供了在 26.2 小时之前停止 GP 抗生素覆盖的机会。只有 8/12(66.7%)对第三代头孢菌素耐药的分离株携带 CTX-M 基因。相比之下,CTX-M 样本的 8/8 个都产生了耐药分离株。在 6/98(6.1%)患者中,检测到 1 株嗜麦芽窄食单胞菌(18 小时)、1 株 OXA23/48 鲍曼不动杆菌(52.4 小时)和 3 株 CTX-M 分离株(47.1 小时)的无效治疗和 1 株(72.6 小时)次优治疗,这将使 6/98(6.1%)患者能够更早地优化抗菌药物治疗。GenMark Dx ePlex 快速血培养诊断系统可更早地鉴定引起血流感染的耐药革兰氏阴性菌。它排除革兰氏阳性菌的能力使 63/98(64.3%)患者的平均提前时间为 26.2 小时,提前停止不必要的抗生素治疗。检测携带 CTX-M 基因的细菌以及早期鉴定出像嗜麦芽窄食单胞菌和鲍曼不动杆菌这样的高度耐药细菌,使 6/98(6.1%)患者能够优化无效治疗。在临床微生物学实验室中实施该系统可优化治疗并改善患者护理。